Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Piramal Enterprises Ltd Stock Analysis

Large Cap
Evaluated by 3518 users | BSE: 500302 | NSE: PEL |
Pharmaceuticals & Drugs

Piramal Enterprises Limited (PEL) is one of India’s leading diversified companies, with a presence in Financial Services and Pharmaceuticals. Driven by both organic as well as inorganic strategy, PEL has steered dynamic business growth over the three...

1. Right Stock
Very Good
2. Right Price
3. Right Time

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Piramal Enterprises Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation
 Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed 0.23%0.52%0.53%6.67%6.14%7.07%12.36%6.44%4.24%5.79%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 2,1593,5204,5035,1236,3428,50410,63113,21514,42312,80912,809
Y-o-Y Gr. Rt.-63.1%27.9%13.8%23.8%34.1%25%24.3%9.1%-11.2%-
Adjusted EPS (Rs.) -6.84-18.04-35.8151.1145.0968.37275.44110.36-18.6858.358.67
Y-o-Y Gr. Rt.-NANANA-11.8%51.6%302.9%-59.9%-116.9%NA-
Book Value per Share (Rs.) 632.35603.18524.3660.13728.33837.121,438.631,440.681,355.421,508.221506.89
Adjusted Net Profit -122-321-6379098021,2165,0862,085-4211,3151,332
Net Op. Cash Flow (Rs. Cr.) -685-1,570-1,604-2,207-6,956-10,057-15,967-11,6117,5163,665-
Debt to Cash Flow from Ops -2.99-4.9-5.95-3.31-2.34-3.03-2.77-4.835.610.74-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Piramal Enterprises Ltd. should be analysed on a Consolidated basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 21.9%15.1%6.4%-11.2%
Adjusted EPS NA5.3%-40.4%NA
Book Value per Share 10.115.71.611.3
Share Price 18.5% 8.4% -3.9% 58.6%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) -1.05-2.92-6.358.636.58.7424.557.75-1.464.073.89
Operating Profit Margin (%) -0.0411.8514.3117.3626.7341.2348.5353.6843.4859.2358.37
Net Profit Margin (%) -5.46-8.83-14.0514.639.5812.2945.213.34-6.348.2510.4
Debt to Equity 0.180.721.020.621.262.051.662.061.381.160.83
Working Capital Days 1,8689927626655835508031,1171,2231,320526
Cash Conversion Cycle 7148475538168-7-7-1173
Corporate Governance What do we look at?
Corporate Governance
Board Credentials
Promoter's holding
Transparency
Integrity
Entity Percentage Holding
Promoters 43.52%
Institutions 43.08%
Non-Institutions 13.40%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

MoneyWorks4Me analysed the past 10-year performance of Piramal Enterprises Ltd and arrived at the following conclusion:

Past 10 year's financial track record indicates that Piramal Enterprises Ltd is a good quality company. However, for specific investment actions please connect with your investment advisor.

The 5-year analysis of Piramal Enterprises Ltd's performance infers:

Piramal Enterprises Ltd earnings have grown by 5.3%, whereas share price has appreciated 8.4% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Piramal Enterprises Ltd share prices over the last 10 years. Here is what we found out:

Piramal Enterprises Ltd share price has appreciated 19.5% annually over the past ten years.

Piramal Enterprises Limited (PEL) is one of India’s leading diversified companies, with a presence in Financial Services and Pharmaceuticals. Driven by both organic as well as inorganic strategy, PEL has steered dynamic business growth over the three decades of its existence.

PEL made its foray into the financial services sector with Piramal Capital & Housing Finance Limited (PCHFL), a housing finance

Piramal Enterprises Limited (PEL) is one of India’s leading diversified companies, with a presence in Financial Services and Pharmaceuticals. Driven by both organic as well as inorganic strategy, PEL has steered dynamic business growth over the three decades of its existence.

PEL made its foray into the financial services sector with Piramal Capital & Housing Finance Limited (PCHFL), a housing finance company registered with the National Housing Bank (NHB) that is engaged in various financial services businesses. It provides end-to-end financing solutions in both wholesale and retail funding opportunities across sectors such as real estate and infrastructure, renewable energy, hospitality, logistics, industrials, auto components etc. Through its group companies, the platform has strategic partnerships with leading global pension funds such as Canadian Pension Plan Investment Board (CPPIB), APG and Ivanhoe Cambridge.

Products and services offered by the company

Piramal Pharma

  • Pharma Solutions
  • Critical Care
  • Consumer Products
  • PhytoMedicine

Financial Services

  • Piramal Capital & Housing Finance
  • India Resurgence Fund (IndiaRF)

Awards & Recognitions

For Financial Services

  • Piramal Capital & Housing Finance Limited was awarded Best Overall Investment Manager for Real Estate in India at the 15th Annual Euromoney Real Estate Survey 2019 - September 2019.
  • Piramal Capital & Housing Finance Limited won ?Best Private Equity Deal of the Year at the 11th Estate Awards by Franchise India - August 2019.
  • Piramal Capital & Housing Finance Limited was awarded ?Best In-House Legal Team of the Year in the Banking and Financial Services sector at the Asian Legal Business India Law Awards 2020 - March 2020.

For Pharma

  • Piramal Pharma Solutions was honoured with the ?Frost & Sullivan Global Customer Service Leadership Award - June 2019.
  • Piramal Pharma Solutions was ranked 1st by Biospectrum India in Bio Services - October 2019.
  • Piramal Pharma Solutions won the ?2020 Manufacturing Supply Chain Operational Industry Excellence Award within the Pharmaceuticals Category at the 9th Edition of Manufacturing Supply Chain Awards - March 2020. 

Milestones

  • 1980: In the early 1980s a young Ajay Piramal takes the reins of the Piramal Group.
  • 1984: Acquired Gujarat Glass
  • 1988: Acquired Nicholas Laboratories.
  • 1990: Gujarat Glass is merged with the group company, Nicholas Piramal India Ltd
  • 1991: A new formulation plant at Pithampur in Madhya Pradesh is commissioned.
  • 1992: Set up a second formulation plant at Pithampur in Madhya Pradesh with state-of-the-art manufacturing facilities.
  • 1992: Nicholas Laboratories Ltd. renamed to Nicholas Piramal India, Ltd.
  • 1993: Piramal entered into a joint venture agreement with Allergan of U.S.A., the leading manufacturers of Ophthalmic products.
  • 1994: A joint venture agreement was entered into with Satelec, France for dental care products.
  • 1995: The bulk drug division of Sumitra Pharmaceutical and Chemicals Ltd. Hyderabad transferred to NPIL.
  • 1996: Entered into a product tie-up with F. Hoffman-La-Roche.
  • 1996: Boehringer Mannheim is acquired.
  • 1997: NPIL entered into an agreement with Reckitt & Colman for joint marketing of the latter's OTC products in India.
  • 1998: Acquired the research unit of Hoechst Marion Roussel (India) in Mumbai.
  • 1998: Nicholas Piramal India Ltd (NPIL) forges joint venture with Boots Healthcare International (BHI) to develop and market consumer healthcare products in India.
  • 2000: Rhone Poulenc India Limited is acquired.
  • 2000: Started collaborative research with Centre for Biochemical Technology in the field of gene technology.
  • 2000: Research alliance established with Hindustan Lever for developing Cosmoceuticals and personal care products.
  • 2002: ICI Pharma is acquired.
  • 2003: Global Bulk Drugs is acquired.
  • 2004: Nicholas forges alliance with scientists from Imperial College of the UK to carry out research in the field of rheumatoid arthritis.
  • 2005: Avecia Pharmaceutical is acquired.
  • 2006: Pfizer's Morpeth UK facility acquired.
  • 2007: Scientists from Piramal led the first exploration by an Indian pharmaceutical company to develop drug leads from geographies like Antarctica.
  • 2008: Khandelwal Laboratories is acquired.
  • 2009: RxEliteinc, the U.S. based inhalation anesthetic gas distribution business, is acquired.
  • 2010: Biosyntech, Inc., Canada is acquired by Piramal Enterprises Ltd., part of the Life Sciences vertical, Bio-Orthopedics division.
  • 2010: Piramal sells the diagnostics division to Super Religare Laboratories Ltd.
  • 2010: Acquisition of iPill, an oral contraceptive brand, from Cipla.
  • 2011: Bharat Serum and Vaccines Ltd - Anaesthetics business buyout by Piramal Enterprises Ltd.
  • 2011: Piramal Realty acquires Mafatlal Mills in Byculla, Mumbai.
  • 2011: Piramal Healthcare acquires 11% of Vodafone India.
  • 2011: UN Conference on Trade and Development’s World Investment Report 2011 ranks Piramal Healthcare as No. 5 in the top 10 pharmaceutical contract manufacturers worldwide.
  • 2011: Piramal Healthcare acquires Indiareit, a real estate focused investment trust with AUM of $760 million.
  • 2011: Fortune 500 ranks Piramal Healthcare in the top-50 largest corporations across India.
  • 2011: Piramal's Pharma Solutions manufacturing site at Grangemouth, Scotland becomes the world’s first contract supplier at commercial scale for ADCs.
  • 2011: Piramal Healthcare acquires Indiareit, a real estate focused investment trust with AUM of $760 million.
  • 2012: Piramal Realty wins the auction of the landmark Hindustan Unilever training centre at Worli Sea Face, Mumbai.
  • 2012: Decision Resources Group acquires Abacus International, a UK based global market access solutions company for many of the world’s leading health care companies.
  • 2012: BST-CarGel, company’s innovative bio-orthopedic product for cartilage repair, receives European CE mark approval.
  • 2012: Piramal Enterprises starts a Non-Banking Financial Company (NBFC) focused on lending to real estate, education and hospitals
  • 2012: Piramal Enterprises acquires health care information management firm, Decision Resources Group, USA for US$635 million
  • 2012: Piramal Realty, a privately owned real estate entity, was formed
  • 2012: Piramal Healthcare Limited is renamed to Piramal Enterprises Limited.
  • 2013: Piramal Enterprises Limited acquires Molecular Imaging Development portfolio of Bayer Pharma
  • 2013: Imaging division's lead radiopharmaceutical, Florbetaben, accepted for review by the US FDA and EMA for the visual detection of Beta-Amyloid in Alzheimer's disease
  • 2013: Piramal Water (Sarvajal) honoured with 'Enabling Technology Award of the Year 2013' by Frost & Sullivan
  • 2013: Piramal Enterprises Ltd. consumer products' division acquires the brand CALADRYL® in India.
  • 2014: APG Asset Management, the Dutch pension fund asset manager and Piramal Enterprises Limited announce a strategic alliance for investing in rupee denominated mezzanine instruments issued by infrastructure companies in India with a target investment of US$1 billion, over the next 3 years
  • 2014: Piramal Enterprises Limited acquires 9.99% equity stake in Shriram City Union Finance Limited
  • 2014: Piramal Enterprises Limited agrees to acquire an effective 20% equity stake in Shriram Capital Limited, a financial services company, for an aggregate consideration of INR 20.14 Billion
  • 2014: Canada Pension Plan Investment Board (CPPIB) and Piramal Enterprises Limited announce a US$500 million Strategic Alliance for Residential Development Debt Financing in India; appoint Piramal Fund Management (at the time known as Indiareit) as advisor
  • 2015: Piramal Enterprises Ltd. acquires Kentucky based Specialty Pharmaceutical CDMO, Coldstream Laboratories Inc.
  • 2015: DRG has acquired Healthcare Business Insights (HBI), a trusted provider of best Practice research, training and services to more than 1,400 hospitals across the U.S.
  • 2015: Warburg Pincus to invest Rs 1800 crore in Piramal Realty.
  • 2015: Piramal Realty secures $150 million (Rs 900 crore) from Goldman Sachs.
  • 2015: Piramal Realty launches a new community for natural and holistic living at Balkum, Thane, Mumbai: Piramal Vaikunth
  • 2015: Piramal Enterprises acquires the Baby Care brand – Little’s for the Consumer Products Business
  • 2016: Piramal Enterprises announces the sale of its Canada-based cartilage repair product, BST-CarGel® to Smith & Nephew
  • 2016: Piramal Realty launches its signature project, Piramal Aranya in Byculla, Mumbai
  • 2016: Piramal Enterprises enters an agreement to acquire four brands from Pfizer Limited for its Consumer Products Business
  • 2016: Piramal Realty forays into commercial real estate with the launch of Piramal Agastya Corporate Park in Kurla, Mumbai
  • 2016: Piramal Enterprises enters into an agreement to acquire Ash Stevens Inc., a US based Contract and Drug Manufacturing Organisation (CDMO) for High Potency APIs (HPAPIs)
  • 2016: Piramal Enterprises Limited and Bain Capital Credit to pursue distressed debt investing in India
  • 2016: Piramal Enterprises Critical Care Division expands its product portfolio; enters into an agreement to acquire Janssen's Injectable Anaesthesia and Pain Management products
  • 2016: Piramal Enterprises Critical Care Division expands its product portfolio; enters into an agreement to acquire Janssen's Injectable Anaesthesia and Pain Management products
  • 2016: Piramal Fund Management launches an Innovative Flexi Lease Rental Discounting (LRD) for Commercial Assets.
  • 2017: Piramal Enterprises Limited announces its plan to enter Housing Finance
  • 2017: Piramal Enterprises Limited and Ivanhoé Cambridge announce Partnership to Invest in Residential Developments in India
  • 2017: Piramal Realty marks exclusive pre-Launch of Piramal Revanta
  • 2017: Piramal Enterprises Completes the Acquisition of a Portfolio of Drugs for Spasticity and Pain Management from Mallinckrodt LLC.
  • 2018: Piramal Finance Limited Forays into the Hospitality Sector
  • 2018: Piramal Realty launches Piramal Mahalaxmi, its Flagship Project in South Mumbai
  • 2018: NITI Aayog Partners with Piramal Foundation to Transform 25 Aspirational Districts across 7 states in India, in the areas of Health & Nutrition and Education.
  • 2018: IndiaRF Announces $156 million Investment in Archean Group’s Marine Chemicals Business.
  • 2019: Piramal Enterprises Limited signed a Memorandum of Understanding with Canada Pension Plan Investment Board (CPPIB) to set-up Asset Aggregation Platform focused on renewables.
  • 2019: Supreme Court Exempts Saridon from the List of Banned FDCs.
  • 2019: Piramal Swasthya has been recognized by USAID with the ‘Inclusive Health Access Award’ for its High Impact Healthcare Platform
  • 2019: Piramal Foundation and Gates Foundation Partner to Setup a Tribal Health Collaborative for India
  • 2019: Piramal Swasthya and The Rockefeller Foundation Announce Partnership to Accelerate India’s Public Health Transformation
  • 2019: Piramal Divests its DRG Business for $950 million.
  • 2019: PEL raises funds of Rs 14,500 crore in FY2020.
  • 2019: Piramal Realty Makes a Foray into Value Housing Segment
  • 2020: Piramal Group Commits INR 25 Crores to COVID-19 Relief Effort.
  • 2020: Carlyle and Piramal Pharma Sign Agreement on 20% Strategic Growth Investment.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback